Candel Therapeutics, Inc.

NasdaqGM:CADL Stock Report

Market Cap: US$157.2m

Candel Therapeutics Past Earnings Performance

Past criteria checks 0/6

Candel Therapeutics's earnings have been declining at an average annual rate of -19.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 40.8% per year.

Key information

-19.1%

Earnings growth rate

6.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-40.8%
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway

Jul 01

Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer

Apr 15

Candel gets European orphan drug designation for brain, spinal cord tumor treatment

Sep 15

Candel Therapeutics appoints CFO, chief medical officer

Sep 07

Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies

Oct 21

Revenue & Expenses Breakdown

How Candel Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:CADL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-5214-4
30 Jun 240-50140
31 Mar 240-37140
31 Dec 230-38140
30 Sep 230-321416
30 Jun 230-32150
31 Mar 230-27150
31 Dec 220-19150
30 Sep 220-12160
30 Jun 220-20150
31 Mar 220-33130
31 Dec 210-36110
30 Sep 210-48103
30 Jun 210-3588
31 Mar 210-2078
31 Dec 200-1868
31 Dec 190-830

Quality Earnings: CADL is currently unprofitable.

Growing Profit Margin: CADL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CADL is unprofitable, and losses have increased over the past 5 years at a rate of 19.1% per year.

Accelerating Growth: Unable to compare CADL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CADL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: CADL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies